supp.fit

Artemisinin: study protocols

63 study groups say how much Artemisinin participants took a day. These are the doses the studies gave. They are not a recommendation.

Artemisinin: what the research found →

Dose per serving from products

40 products in our catalogue print how much Artemisinin a serving holds.

Most common: 100 mg to 250 mg, 53% of 40 products.

Dose per servingProducts
10 mg to 25 mg
3
25 mg to 50 mg
1
50 mg to 100 mg
9
100 mg to 250 mg
21
250 mg to 500 mg
2
500 mg to 1 g
4

Dose per serving from research

40 study groups in 24 studies say how much Artemisinin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 25 mg to 50 mg, 33% of 40 study groups.

Daily doseStudy groups
10 mg to 25 mg
3
25 mg to 50 mg
13
50 mg to 100 mg
3
100 mg to 250 mg
8
250 mg to 500 mg
12
over 500 mg
1

Commonly used together

34 of 63 study groups took Artemisinin with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
piperaquine
10
amodiaquine
5
lumefantrine
3
naphthoquine
3

63 study groups

Study
Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda
2005 · AQ + AS · Patients aged 6 months or older with uncomplicated Plasmodium falciparum malaria; both sexes, not pregnant
4 mg/kg3 days731
Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial
2020 · PZQ+DHP · School-going children aged 7–17 years with Schistosoma mansoni intestinal schistosomiasis in rural Tanzania
40 mg3 days298
A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy
2008 · artesunate (AS7) · Pregnant women in the second or third trimester with acute uncomplicated Plasmodium falciparum malaria
2 mg/kg7 days128
Single dose artemisinin-mefloquine versus mefloquine alone for uncomplicated falciparum malaria
1997 · AM · Patients with uncomplicated falciparum malaria
500 mg1 day117
Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo
2006 · AL (artemether-lumefantrine) · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria who weighed at least 10 kg
40 mg3 days106
Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo
2006 · AS + AQ · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria
4 mg/kg3 days101
Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo
2006 · AS + SP · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria
4 mg/kg3 days91
Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand
2003 · Group A (DNP) · Adults older than 14 years and over 40 kg with acute uncomplicated falciparum malaria
320 mg1 day89
Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania
2007 · AS+AQ (Mlimba site) · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria
4 mg/kg3 days76
The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam
2012 · artemisinin-piperaquine (ARPQ) · Patients aged 5–60 years with uncomplicated Plasmodium falciparum malaria
2.8 mg/kg2 days63
Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia
2007 · Artesunate/Amodiaquine · People aged 1–65 with uncomplicated Plasmodium falciparum malaria
4 mg/kg3 days42
Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand
2003 · Group B (Coartem/Riamet) · Adults older than 14 years and over 40 kg with acute uncomplicated falciparum malaria
40 mg3 days41
Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens
2002 · group A · adult male and female Vietnamese patients with uncomplicated falciparum malaria
500 mg5 days40
Therapeutic equivalence of a low dose artemisinin formulation in falciparum malaria patients
2003 · beta-cyclodextrin-artemisinin complex group · Patients with uncomplicated falciparum malaria
300 mg5 days—
Therapeutic equivalence of a low dose artemisinin formulation in falciparum malaria patients
2003 · commercial reference preparation (Artemisinin 250) group · Patients with uncomplicated falciparum malaria
500 mg5 days—
Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria
1998 · oral treatment · adult Vietnamese men with uncomplicated falciparum malaria
500 mg5 days—
Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial
2023 · dihydroartemisinin–piperaquine group · Pregnant women of any age with a viable singleton pregnancy at 16–28 weeks’ gestation in malaria-endemic areas of Malawi, Tanzania, or Kenya
40 mg131 days1,561
Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial
2023 · dihydroartemisinin–piperaquine plus azithromycin group · Pregnant women of any age with a viable singleton pregnancy at 16–28 weeks’ gestation in malaria-endemic areas of Malawi, Tanzania, or Kenya
40 mg131 days1,558
A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial
2011 · DHAPQ · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria (12–59 months at sites using CD+A)
2.25 mg/kg3 days1,475
A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial
2011 · ASAQ · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria (12–59 months at sites using CD+A)
2.8 mg/kg3 days1,002
An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia
2010 · DHA/PQP · Males and females aged 3 months to 65 years with uncomplicated, microscopically confirmed falciparum or mixed malaria; Indian participants were aged 18 years or older
2.25 mg/kg3 days767
Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children
2019 · DHA-PQ group · Children aged 2.33–58.1 months in Burkina Faso, apparently healthy and living in an area of intense seasonal malaria transmission
2 mg/kg90 days754
A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages
2018 · Intervention (early MDA) · Residents of four Cambodian forest-fringe villages; all ages except infants under 6 months, pregnant or lactating women, and people with acute health problems
7 mg/kg90 days668
Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial
2015 · Intermittent preventive treatment with dihydroartemisinin–piperaquine · HIV-negative pregnant women, 16–32 weeks’ gestation, without a stated diagnosis.
80 mg—516
Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial
2009 · AS-SMP 3 days · People aged over 6 months with uncomplicated P. falciparum malaria; both sexes; pregnant people excluded
200 mg3 days476
Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial
2009 · AS-SMP 24 hours · People aged over 6 months with uncomplicated P. falciparum malaria; both sexes; pregnant people excluded
200 mg2 days458
Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial
2009 · AL 3 days · People aged over 6 months with uncomplicated P. falciparum malaria; both sexes; pregnant people excluded
40 mg3 days450
An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia
2010 · AS+MQ · Males and females aged 3 months to 65 years with uncomplicated, microscopically confirmed falciparum or mixed malaria; Indian participants were aged 18 years or older
4 mg/kg3 days381
Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial
2010 · AQ3-AS3 · Infants aged 5–16 weeks at enrolment in rural western Kenya
25 mg3 days347
Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial
2010 · SP-AS3 · Infants aged 5–16 weeks at enrolment in rural western Kenya
25 mg3 days339
A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru
2007 · DHA-PPQ · Patients aged 5–60 with uncomplicated Plasmodium falciparum malaria
2.1 mg/kg3 days262
A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru
2007 · MAS3 · Patients aged 5–60 with uncomplicated Plasmodium falciparum malaria
4 mg/kg3 days260
Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial
2014 · artemisinin-naphthoquine · Children aged 0.5–5 years with uncomplicated P. falciparum or P. vivax malaria
20 mg/kg3 days127
A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy
2008 · artemether-lumefantrine (AL) · Pregnant women in the second or third trimester with acute uncomplicated Plasmodium falciparum malaria
40 mg3 days125
A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children
2008 · ASAQ · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria
50 mg3 days123
A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children
2008 · AL · Children aged 6–59 months with uncomplicated Plasmodium falciparum malaria
40 mg3 days123
[A randomized clinical trial comparing the effectiveness and tolerability of artemisinine-naphthoquine (Arco®) and artemether-lumefantrine (Coartem®) in the treatment of uncomplicated malaria in Benin]
2012 · Arco® group · Children with uncomplicated falciparum malaria; age range and sex not specified
125 mg1 day84
Population pharmacokinetics of artesunate and amodiaquine in African children
2009 · AS+AQ (loose combination) · Children aged 6 months to 5 years, both sexes, with acute uncomplicated Plasmodium falciparum malaria
4 mg/kg3 days70
Population pharmacokinetics of artesunate and amodiaquine in African children
2009 · AS/AQ (fixed-dose combination) · Children aged 6 months to 5 years, both sexes, with acute uncomplicated Plasmodium falciparum malaria
4 mg/kg3 days70
Efficacy of Artequick versus artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand
2008 · Group A (Artequick) · Adults aged 15 years or older, weighing at least 40 kg, with acute uncomplicated falciparum malaria
3.2 mg/kg3 days65
Open-label trial of three dosage regimens of fixed-dose combination of artemisinin and naphthoquine for treating uncomplicated falciparum malaria in Calabar, Nigeria
2012 · Group B · Adults and adolescents aged 15 years or older with uncomplicated falciparum malaria
250 mg1 day35
A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women
2007 · SP plus artesunate · Pregnant women aged 15–49 with uncomplicated Plasmodium falciparum infection, 14–26 weeks’ gestation
200 mg—47
Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial
2009 · MB-AS group · Children aged 6–10 years with uncomplicated falciparum malaria
4 mg/kg3 days61
Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial
2009 · AS-AQ group · Children aged 6–10 years with uncomplicated falciparum malaria
4 mg/kg3 days61
Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study
2011 · T1 (micronized artemisinin powder, test formulation) · Healthy Vietnamese men aged 18–55 years
160 mg1 day15
Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study
2011 · T2 (reference Vietnamese low-dose formulation) · Healthy Vietnamese men aged 18–55 years
160 mg1 day15
Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study
2011 · T3 (reference Vietnamese dose-strength formulation) · Healthy Vietnamese men aged 18–55 years
500 mg1 day15
Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study
2011 · T4 (fixed artemisinin-piperaquine tablet formulation) · Healthy Vietnamese men aged 18–55 years
160 mg1 day15
Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers
2001 · Group AS · Healthy Vietnamese males
500 mg11 days10
Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers
2001 · Group AM · Healthy Vietnamese males
500 mg11 days10
Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria
2002 · Artemisinin 500 mg daily for 3 days followed by mefloquine on day 4 · Male and female patients with Plasmodium falciparum malaria
500 mg3 days—
Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria
2002 · Artemisinin 500 mg daily for 3 days plus mefloquine on day 1 · Male and female patients with Plasmodium falciparum malaria
500 mg3 days—
A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction
2005 · Daily single-dose regimen · Healthy males
500 mg24 days—
Efficacy and tolerance of artemisinin in short combination regimens for the treatment of uncomplicated falciparum malaria
1996 · AQ · Patients with uncomplicated falciparum malaria; age and sex not specified
20 mg/kg4 days—
Efficacy and tolerance of artemisinin in short combination regimens for the treatment of uncomplicated falciparum malaria
1996 · AD · Patients with uncomplicated falciparum malaria; age and sex not specified
20 mg/kg4 days—
The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum
2009 · AS/AQ (fixed) · Children aged 6 months to 5 years with acute uncomplicated Plasmodium falciparum malaria
25 mg3 days375
The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum
2009 · AS+AQ (loose) · Children aged 6 months to 5 years with acute uncomplicated Plasmodium falciparum malaria
50 mg3 days375
Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention
2017 · HIV-uninfected pregnant women receiving DHA-piperaquine · Pregnant HIV-uninfected women enrolled between 12 and 28 weeks gestation
40 mg3 days31
Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol
2014 · Arm B · Healthy male and nonpregnant female volunteers aged 18–55 years
60 mg9 weeks30
Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention
2017 · HIV-uninfected non-pregnant women receiving DHA-piperaquine · HIV-uninfected non-pregnant women at least 12 weeks postpartum
40 mg3 days30
Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention
2017 · HIV-infected pregnant women receiving EFV-based ART and DHA-piperaquine · Pregnant HIV-infected women receiving EFV-based antiretroviral therapy
40 mg3 days27
Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol
2014 · Arm A · Healthy male and nonpregnant female volunteers aged 18–55 years
60 mg93 days26
[Study on effect of Cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis]
2002 · treated group · Patients with lupus nephritis whose disease was inactive after corticosterone and cyclophosphamide therapy
600 mg3 years31